LATe TreatmENT Related Toxicity in Melanoma (LATENT)
This study, called LATENT, is investigating the long-term side effects of modern immunotherapy treatments for advanced melanoma. While these treatments have greatly improved survival, some patients experience side effects that can last for years, and we don't know enough about them. Researchers will confidentially look at existing medical records of about 400 patients who have had a lasting positive response to immunotherapy for at least three years. They will collect information on how often these side effects occur and how severe they are. The goal is to better understand these long-term issues, so that healthcare teams can develop improved support and care plans for patients living well after treatment.
Em resumo
Sobre o que é este estudo?
This study is called LATENT, which stands for LATe TreatmENT Related Toxicity in Melanoma. In simple terms, it's about understanding the long-term effects of treatments for advanced melanoma. Melanoma is a serious type of skin cancer, and over the past few years, we've seen fantastic progress with new medicines called immunotherapies. These treatments help your body's own immune system fight the cancer, and they have greatly improved how long people live with advanced melanoma.
While these treatments are very effective, they can also cause side effects. We know about the short-term side effects that many patients experience during treatment. However, because more people are now living longer after treatment, doctors are realising that some patients experience side effects that last for years — these are the 'late-term' effects. At the moment, we don't have enough clear information about how often these long-term side effects happen, how serious they are, or how they affect people's daily lives.
That's why this study is so important. Researchers from leading hospitals like Clatterbridge and Christie's are working together to look back at the medical records of around 400 patients. They will specifically focus on patients who have had advanced melanoma, received immunotherapy, and have responded well to treatment for at least three years. By carefully reviewing these records, the team hopes to build a clearer picture of these late side effects. The information they gather will help doctors provide better, more tailored care and support for patients living well after immunotherapy, making sure any long-term issues are properly managed.
Pontos principais
- This study investigates long-term side effects of immunotherapy for advanced melanoma.
- It uses existing, anonymised medical records, so no direct patient involvement is needed.
- Focuses on patients who had a good, lasting response to treatment (at least 3 years).
- Aims to improve future patient care and support for those with long-term side effects.
- Your personal details will be kept completely confidential and made anonymous.
Quem pode ser elegível?
This study is looking at information from medical records of people who have already been treated for melanoma. To be included, the original diagnosis must have been melanoma, and the person must have been 18 years or older when they received treatment.
They would have been treated for advanced melanoma (meaning the cancer had spread or was difficult to remove surgically) between January 2005 and December 2020. The treatment they received must have been one of the specific immunotherapy drugs like Pembrolizumab, Nivolumab, Ipilimumab, or a combination of these. Importantly, they must have had a good, lasting response to this treatment for at least three years.
You would not be included if you had other active cancers needing treatment at the time, or if your immunotherapy was only for early-stage melanoma, or if you received other main treatments after immunotherapy. Also, if your melanoma got worse during or after immunotherapy, your records would not be used for this particular study, as the focus is on long-term responders.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Did you have a melanoma diagnosis?
- Were you 18 or older when treated?
- Did you receive immunotherapy for advanced melanoma between 2005-2020?
- Did you respond well to treatment for at least three years?
- Did you not have other active cancers needing treatment at the time?
O que envolve a participação?
You won't actually be asked to do anything for this study. Because it's an 'observational' study, researchers will simply look at information that is already in your past medical records. This means there are no extra hospital visits, no new tests, no treatment changes, and no follow-up appointments for you specifically related to this study. Your care will continue as normal. Your medical data will be kept private and anonymised, meaning your name and other identifying details will be removed so the researchers can't tell who you are.
Riscos e benefícios potenciais
Localizações (1)
- Royal Marsden NHS Foundation TrustCódigo postal verificadoChelsea, United Kingdom
Perguntas frequentes
What is immunotherapy?
Immunotherapy is a type of cancer treatment that helps your body's own immune system fight cancer cells more effectively.
What are 'long-term side effects'?
These are health problems or symptoms that people experience for many months or even years after their cancer treatment has finished.
Will my personal details be safe?
Yes, absolutely. The researchers will remove all personal details from your medical records before they study the information, so you cannot be identified.
Do I need to do anything to be part of the study?
No, you don't need to do anything. Researchers will use existing, anonymised information from medical records if it fits the study criteria.
How will this study help patients?
By understanding more about long-term side effects, doctors hope to create better support and care plans for patients living well after melanoma immunotherapy.
Como saber mais
Arjun Modi
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.